Inlyta (Axitinib) Patent Expiration, LOE Window & CMS Spending

Inlyta (Axitinib) by Pfizer: FDA Orange Book core substance LOE 2031-06-14 (last listed 2037-07-12), 1 AB generics, $489.5M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN202324 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-06-14
Last Listed Patent or Exclusivity Date2037-07-12
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$489.5M
2024 Medicare Part D Spend$438.9M
2024 Medicaid Spend$50.6M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 26.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.